Literature DB >> 7556981

Insertion/deletion polymorphism in the angiotensin-I-converting enzyme gene is associated with coronary heart disease in IDDM patients with diabetic nephropathy.

L Tarnow1, F Cambien, P Rossing, F S Nielsen, B V Hansen, L Lecerf, O Poirier, S Danilov, S Boelskifte, K Borch-Johnsen.   

Abstract

Insulin-dependent diabetic (IDDM) patients with diabetic nephropathy have a highly increased morbidity and mortality from coronary heart disease. An insertion (I) /deletion (D) polymorphism in the angiotensin-I-converting enzyme (ACE) gene has been shown to be associated with coronary heart disease. Therefore, we have investigated the role of this ACE/ID polymorphism in 198 IDDM patients with diabetic nephropathy and 190 normoalbuminuric IDDM patients. The prevalence of myocardial infarction and other coronary heart disease was significantly elevated in patients with nephropathy, 19% (38/198) vs 8% (15/190), p < 0.001. In the nephropathic group 12 of 63 (19%), 23 of 95 (24%), and 3 of 40 (7.5%) patients with the DD, ID and II genotypes, respectively had a history of coronary heart disease, II vs DD and ID, p < 0.05 when compared to nephropathic patients without coronary heart disease. Multiple logistic regression analysis of the risk factors associated with coronary heart disease in univariate analysis revealed that the II genotype acts as an independent protective factor against coronary heart disease, odds ratio II/DD + ID 0.27 (95% confidence interval 0.07-0.97, p < 0.05). There was no difference in genotype or allele frequency (D/I) between patients with and without nephropathy, 0.56/0.44 in both groups, but plasma ACE concentration was elevated in patients with nephropathy 609 (151-1504) ng/ml as compared to patients with normoalbuminuria, 428 (55-1630) ng/ml, p < 0.001. We suggest that ACE/ID polymorphism may influence the frequency of life-threatening cardiac complications in IDDM patients suffering from diabetic nephropathy, a condition characterized by increased plasma ACE concentration.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7556981     DOI: 10.1007/s001250050355

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  34 in total

1.  Angiotensin-converting enzyme gene polymorphism in haemodialysis patients.

Authors:  H Nomura; I Koni; Y Michishita; T Morise; R Takeda
Journal:  Lancet       Date:  1994-02-19       Impact factor: 79.321

2.  Multicentre study of a new enzymatic method of cholesterol determination.

Authors:  R Kattermann; D Jaworek; G Möller; G Assmann; I Björkhem; L Svensson; K Borner; G Boerma; B Leijnse; J P Desager
Journal:  J Clin Chem Clin Biochem       Date:  1984-03

3.  Angiotensin-converting enzyme polymorphism in hypertrophic cardiomyopathy and sudden cardiac death.

Authors:  A J Marian; Q T Yu; R Workman; G Greve; R Roberts
Journal:  Lancet       Date:  1993-10-30       Impact factor: 79.321

4.  Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions.

Authors:  S Yusuf; C J Pepine; C Garces; H Pouleur; D Salem; J Kostis; C Benedict; M Rousseau; M Bourassa; B Pitt
Journal:  Lancet       Date:  1992-11-14       Impact factor: 79.321

5.  Absence of linkage between the angiotensin converting enzyme locus and human essential hypertension.

Authors:  X Jeunemaitre; R P Lifton; S C Hunt; R R Williams; J M Lalouel
Journal:  Nat Genet       Date:  1992-04       Impact factor: 38.330

6.  Diabetic nephropathy in Type 1 (insulin-dependent) diabetes: an epidemiological study.

Authors:  A R Andersen; J S Christiansen; J K Andersen; S Kreiner; T Deckert
Journal:  Diabetologia       Date:  1983-12       Impact factor: 10.122

7.  Relationships between angiotensin I converting enzyme gene polymorphism, plasma levels, and diabetic retinal and renal complications.

Authors:  M Marre; P Bernadet; Y Gallois; F Savagner; T T Guyene; M Hallab; F Cambien; P Passa; F Alhenc-Gelas
Journal:  Diabetes       Date:  1994-03       Impact factor: 9.461

8.  Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy.

Authors:  H H Parving; A R Andersen; U M Smidt; P A Svendsen
Journal:  Lancet       Date:  1983-05-28       Impact factor: 79.321

9.  PCR detection of the insertion/deletion polymorphism of the human angiotensin converting enzyme gene (DCP1) (dipeptidyl carboxypeptidase 1).

Authors:  B Rigat; C Hubert; P Corvol; F Soubrier
Journal:  Nucleic Acids Res       Date:  1992-03-25       Impact factor: 16.971

10.  Structure-function analysis of angiotensin I-converting enzyme using monoclonal antibodies. Selective inhibition of the amino-terminal active site.

Authors:  S Danilov; E Jaspard; T Churakova; H Towbin; F Savoie; L Wei; F Alhenc-Gelas
Journal:  J Biol Chem       Date:  1994-10-28       Impact factor: 5.157

View more
  12 in total

Review 1.  Diabetic nephropathy. Its relationship to hypertension and means of pharmacological intervention.

Authors:  T Baba; S Neugebauer; T Watanabe
Journal:  Drugs       Date:  1997-08       Impact factor: 9.546

2.  Plasma N-terminal pro-brain natriuretic peptide as an independent predictor of mortality in diabetic nephropathy.

Authors:  L Tarnow; P Hildebrandt; B V Hansen; K Borch-Johnsen; H-H Parving
Journal:  Diabetologia       Date:  2004-12-23       Impact factor: 10.122

3.  Insertion/deletion polymorphism in the angiotensin-I-converting enzyme gene.

Authors:  A Demaine; M Hibberd; A Millward
Journal:  Diabetologia       Date:  1995-12       Impact factor: 10.122

4.  Examination of two genetic polymorphisms within the renin-angiotensin system: no evidence for an association with nephropathy in IDDM.

Authors:  T A Chowdhury; M J Dronsfield; S Kumar; S L Gough; S P Gibson; A Khatoon; F MacDonald; B R Rowe; D B Dunger; J D Dean; S J Davies; J Webber; P R Smith; P Mackin; S M Marshall; D Adu; P J Morris; J A Todd; A H Barnett; A J Boulton; S C Bain
Journal:  Diabetologia       Date:  1996-09       Impact factor: 10.122

5.  The apolipoprotein A-IV Gln360His polymorphism predicts progression of coronary artery calcification in patients with type 1 diabetes.

Authors:  A Kretowski; J E Hokanson; K McFann; G L Kinney; J K Snell-Bergeon; D M Maahs; R P Wadwa; R H Eckel; L G Ogden; S K Garg; J Li; S Cheng; H A Erlich; M Rewers
Journal:  Diabetologia       Date:  2006-06-13       Impact factor: 10.122

6.  Genetics of Kidneys in Diabetes (GoKinD) study: a genetics collection available for identifying genetic susceptibility factors for diabetic nephropathy in type 1 diabetes.

Authors:  Patricia W Mueller; John J Rogus; Patricia A Cleary; Yuan Zhao; Adam M Smiles; Michael W Steffes; Jean Bucksa; Therese B Gibson; Suzanne K Cordovado; Andrzej S Krolewski; Concepcion R Nierras; James H Warram
Journal:  J Am Soc Nephrol       Date:  2006-06-14       Impact factor: 10.121

7.  Aortic atherosclerosis in diabetes mellitus is associated with an insertion/deletion polymorphism in the angiotensin I-converting enzyme gene. No relation between the polymorphism and aortic collagen content.

Authors:  L M Rasmussen; T Ledet
Journal:  Diabetologia       Date:  1996-06       Impact factor: 10.122

8.  The methylglyoxal-derived AGE tetrahydropyrimidine is increased in plasma of individuals with type 1 diabetes mellitus and in atherosclerotic lesions and is associated with sVCAM-1.

Authors:  M G A van Eupen; M T Schram; H M Colhoun; N M J Hanssen; H W M Niessen; L Tarnow; H H Parving; P Rossing; C D A Stehouwer; C G Schalkwijk
Journal:  Diabetologia       Date:  2013-04-26       Impact factor: 10.122

9.  The renin angiotensin system and the metabolic syndrome.

Authors:  Chih-Hong Wang; Feng Li; Nobuyuki Takahashi
Journal:  Open Hypertens J       Date:  2010

10.  Polymorphism of the ACE Gene in dialysis patients: overexpression of DD genotype in type 2 diabetic end-stage renal failure patients.

Authors:  Hyeong Cheon Park; So Rae Choi; Beom Seok Kim; Tae Hee Lee; Byung Seung Kang; Kyu Hyun Choi; Ho Yung Lee; Dae Suk Han; Sung-Kyu Ha
Journal:  Yonsei Med J       Date:  2005-12-31       Impact factor: 2.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.